Core Insights - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is recognized as one of the top biotech stocks to invest in, with RBC Capital maintaining an Outperform rating and increasing its price target from $435 to $500 due to strong sales data for Amvuttra [1][2] Sales Performance - Amvuttra generated $167 million in revenues in August, marking a 17% increase from July, a 40% growth from June, and a 238% spike from February until the launch of cardiomyopathy (CM) [2] - RBC Capital projects that Amvuttra's peak sales could reach $9.3 billion, up from an earlier estimate of $7.9 billion [2] Financial Guidance - The firm anticipates that Alnylam Pharmaceuticals could raise its TTR guidance by approximately $300 million, bringing it to around $2.5 billion [2] Company Overview - Alnylam Pharmaceuticals is a leading biopharmaceutical company specializing in RNA interference (RNAi) treatments, with several FDA-approved medications for rare genetic diseases [3]